After a decade of outpacing the market, are we finally going to see a plateau in the growth of orphan drugs? Well, maybe. Data-wise, there’s only a hint of that being the case, but there are some significant headwinds for companies developing these treatments for rare diseases. The Inflation Reduction Act (IRA) combined with successes across more…
What’s the big deal about orphan drugs? Well, they form the fastest-growing segment of the pharma market and dominate FDA approvals for a start. The diseases they treat might be rare, but there is nothing niche about the commitment to their development – and the potential revenues as a result. For a quick spin round the highlights of this…
300 million people around the world live with a rare disease. This perhaps explains the seemingly endless growth of orphan drugs and the forecasted $300bn market by…
After a decade of outpacing the market, are we finally going to see a plateau in the growth of orphan drugs? Well, maybe. Data-wise, there’s only a hint of that being the…
300 million people around the world live with a rare disease. This perhaps explains the seemingly endless growth of orphan drugs and the forecasted $300bn market by…
What’s the big deal about orphan drugs? Well, they form the fastest-growing segment of the pharma market and dominate FDA approvals for a start. The diseases they treat…
This infographic gives you the vital signs of the cardiology landscape. Get a snapshot of the key medtech approvals, the industry players that are driving cardiology…
This infographic gives you the vital signs of the cardiology landscape. Get a snapshot of the key medtech approvals, the industry players that are driving cardiology…
Pharma’s R&D pipeline is its lifeblood. The industry-wide pipeline is today worth a staggering $1.4 trillion. Yet, like many others, you may find that getting R&D…
Close to 40% of the US adult population is now obese and the WHO and AMA define obesity as a disease. So it’s perhaps no surprise that Evaluate Pharma is forecasting…
Pharma’s R&D pipeline is its lifeblood. The industry-wide pipeline is today worth a staggering $1.4 trillion. Yet, like many others, you may find that getting R&D…
